Sildenafil Citrate Tablet
Product Images NDC 71205-657

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 71205-657). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-657-30 (Sildenafil Citrate 100 mg 30s)

Label for Sildenafil Citrate 100 mg tablets from Proficient Rx LP. The bottle contains 30 pale blue to blue, caplet-shaped, film-coated tablets debossed with '1A1'. Each tablet contains Sildenafil citrate USP equivalent to Sildenafil 100 mg. Manufactured by Umedica Laboratories Pvt. Ltd., India. The label includes NDC 71205-657-30 and storage instructions to keep at 25°C (77°F) and out of children's reach.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

Line graph showing mean change from baseline in sitting systolic blood pressure over 24 hours comparing Sildenafil Citrate 100 mg and placebo in healthy volunteers. The x-axis represents time post dose (hours) and the y-axis shows systolic blood pressure change (mmHg). Two data series are plotted, illustrating blood pressure trends after dosing.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' depicting the change in systolic blood pressure (mmHg) over time post-dose (hours). Two lines compare Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg over an 8-hour period, showing blood pressure trends for both groups.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line chart showing the mean change in standing systolic blood pressure over time in hours postdose. It compares two treatment groups: Doxazosin plus Placebo (blue line with circle markers) and Doxazosin plus Sildenafil 50 mg (black line with diamond markers). The y-axis represents the change in blood pressure (mmHg), and the x-axis represents time in hours from 0 to 8.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

A line graph showing mean standing systolic blood pressure change from baseline over 8 hours after dosing. The graph compares two groups: one receiving Doxazosin plus Sildenafil 100 mg and the other receiving Doxazosin plus Placebo, with systolic blood pressure changes on the y-axis and time after dosing in hours on the x-axis.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

Line graph showing mean plasma concentrations of Sildenafil over time after oral administration in healthy male volunteers. The x-axis represents time post dose in hours, and the y-axis shows plasma concentration in ng/mL. The curve peaks sharply early and tapers steadily to near zero by 24 hours, comparing treatment and commercial tablet data.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar charts showing the effect of sildenafil citrate and placebo on the maintenance of erection by baseline score. The vertical axis indicates the percentage of patients at endpoint, and the horizontal axis displays baseline scores from 0 to 5. Different bars represent categories labeled 0 through 5, depicting patient distribution across these categories for both sildenafil citrate and placebo groups.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

Bar chart depicting the percentage of patients reporting improvement across four treatment groups: placebo, Sildenafil citrate 25 mg, 50 mg, and 100 mg. Percent improvement increases with higher doses of Sildenafil citrate, with the 100 mg group showing the highest improvement at 82%.*

FDA Label Image

Sildenafil-citrate-strecture (Sildenafil Citrate Strecture)

Chemical structure of sildenafil citrate, showing the molecular framework of its active ingredient used in oral tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.